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Marisa Baré2,4, Nerea Fernández-de-Larrea5,6, Maximino Redondo2,7, Eduardo Briones6,8,
Antonio Escobar2,9, Cristina Sarasqueta2,10, Susana Garcı́a-Gutierrez1,2,
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Tools to aid in the prognosis assessment of colon cancer patients in terms of risk of mortality
are needed. Goals of this study are to develop and validate clinical prediction rules for 1-
and 2-year mortality in these patients.
Methods
This is a prospective cohort study of patients diagnosed with colon cancer who underwent
surgery at 22 hospitals. The main outcomes were mortality at 1 and 2 years after surgery.
Background, clinical parameters, and diagnostic tests findings were evaluated as possible
predictors. Multivariable multilevel logistic regression and survival models were used in the
analyses to create the clinical prediction rules. Models developed in the derivation sample
were validated in another sample of the study.
Results
American Society of Anesthesiologists Physical Status Classification System (ASA), Charl-
son comorbidity index (> = 4), age (>75 years), residual tumor (R2), TNM stage IV and log of
lymph nodes ratio (> = -0.53) were predictors of 1-year mortality (C-index (95% CI): 0.865
(0.792–0.938)). Adjuvant chemotherapy was an additional predictor. Again ASA, Charlson
Index (> = 4), age (>75 years), log of lymph nodes ratio (> = -0.53), TNM, and residual tumor
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were predictors of 2-year mortality (C-index:0.821 (0.766–0.876). Chemotherapy was also
an additional predictor.
Conclusions
These clinical prediction rules show very good predictive abilities of one and two years sur-
vival and provide clinicians and patients with an easy and quick-to-use decision tool for use
in the clinical decision process while the patient is still in the index admission.
Introduction
Colon cancer is one of the most frequently diagnosed cancers and is increasing in prevalence
in some countries, partly owing to better screening and diagnosis strategies. Despite this
increased prevalence, survival expectancy is improving, owing to earlier detection and better
tools for treatment.[1,2] Most patients will undergo surgery and some will also receive chemo-
therapy. However, mortality remains high and, so, a main outcome of interest. Therefore,
there is concern about the prognosis of these patients in terms of identifying predictors of
mortality based on patient characteristics.[3] For this assessment, prediction models, decision
rules, and risk scores are statistical tools intended to classify patients and guide clinicians in
their everyday decision-making. These tools consist of a combination of multiple predictors,
such as patient characteristics, diagnosis, and evolution, to estimate the probability of a certain
outcome.[4,5] Different researchers have also developed various prediction rules for colon
cancer patients, mainly to predict survival after surgery or very shortly afterwards.[6,7] Five-
year survival prediction has been the outcome of some other studies.[8–10] There are fewer
studies trying to predict survival at a longer period of time, such as 1–2 years.
The goal of this study was to develop clinical prediction rules for 1- and 2-year mortality in
colon cancer patients who underwent surgery with the purpose of helping to personalize treat-
ment and assist in the follow-up of these patients.
Methods
This prospective cohort study included patients drawn from 22 hospitals belonging to the
Spanish National Health Service, which covers the majority of the Spanish population. All cov-
ered residents have free access to their primary care physician and the Emergency Department
(ED) of the hospitals. All of the hospitals have similar technological and human resources.
A description of the study protocol is detailed elsewhere.[11] In summary, patients diag-
nosed with colon cancer presenting at any of these hospitals to undergo surgery between June
2010 and December 2012 were informed of the goals of the study and invited to participate. In
order to take part in the study, a patient had to provide a signed informed consent. All infor-
mation was kept confidential. The Institutional Review Board of the Basque Country approved
this project.
Patients were eligible for the study if they were included in the surgical waiting list of one of
the participating hospitals with a diagnosis of surgically resectable colon cancer. Colon cancer
diagnosis was based on anatomopathological diagnosis after a biopsy by colonoscopy. Inclu-
sion criteria were: 1) having been diagnosed with colon cancer(up to 15 cm above the anal
margin), 2) initial application of curative and/or palliative surgery for treatment, and 3) sign-
ing the informed consent to participate in the study.[12] Exclusion criteria were: 1) colon
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carcinoma in situ, 2) unresectable tumor, 3) severe mental or physical conditions that pre-
cluded the patient from responding to questionnaires, 4) terminal disease, 5) inability to
respond to questionnaires from any cause, and 6) did not give consent to participate in the
study. We estimated the sample size needs of the study based on current recommendations for
clinical prediction rules based on the expected rates of the outcome of interest (mortality at 1
or 2 years).[5,13]
Data collected upon hospital admission included information on sociodemographic factors,
clinical data (including information about onset of symptoms, habits, personal and family
background, comorbidities including those of the Charlson Comorbidity Index,[14] diagnostic
tests, and pre-intervention treatments), preoperative data (including American Society of
Anesthesiologists Physical Status Classification System (ASA) stage,[15] analytical data, tumor
markers, and diagnostic tests), outpatient anesthesia data from the surgical intervention, path-
ological data, and data related to the remainder of the hospital stay (including the presence of
complications, need for reoperation, or death). Subsequently, data were collected up to 30 days
after surgery (analytical data, diagnostic tests, presence of complications, readmissions, reoper-
ation, or death). Finally, patient information was collected through the first and second post-
operative year, including radiation therapy, chemotherapy (treatment schedule, cycles,
complications of treatment, and supportive care), laboratory results and diagnostic tests, pres-
ence of complications, tumor recurrence, readmission or reoperation, and death.
Outcome measures
The primary outcomes were mortality at 1 and 2 years after the patient was first admitted to
the hospital (index admission). Vital status was established by reviewing medical records and
examining the hospital database and public death registries. Deaths were considered con-
firmed if the name, sex, and date of birth on the record matched those of the participant.
Statistical analyses
The unit of analysis was a patient with a diagnosis of colon cancer who underwent operation
in one of the participating hospitals. The sample was randomly divided in two subsamples
(derivation and validation), each with half of the total population. Randomization of patients
was performed automatically by a statistical program. To ease the interpretation of all the
models, as well as, the punctuation of the scores derived from the models, all continuous vari-
ables were categorized. In the case of the age and Charlson comorbidity index, the optimal cat-
egorization of both was performed following the methodology developed by Barrios I et al
[16]. In the case of Log Lymph ratio, categorization of the continuous variable was done based
on the publication of Persiani R et al [17]. Descriptive statistics for both samples included fre-
quencies and percentages for categorical data and means and standard deviations for continu-
ous variables.
Univariable analysis was first performed in the derivation sample to identify risk factors
related to mortality up to 1 and 2 years, using univariable Cox proportional-hazards regression
models. Variables that were significant at a level of 0.20 were considered as potential indepen-
dent variables for the multivariable analysis. Multivariable Cox proportional-hazards regres-
sion models were developed for mortality up to 1 and 2 years. Final predictive factors in
multivariable analysis were those with a significance level of 0.05. Final models were also
adjusted by the treating hospital to see if that affected the results and evaluated in the validation
sample. As an internal validation of the models, 200 bootstrap samples with replacement were
drawn from the original sample, and using for the selection of the variables stepwise method,
200 different models were developed in each sample. In order to compare the results of the 200
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models with the model fitted in the original sample, the times that different predictors were
predictors in the final models of each sample were summarized. Additionally, presence of col-
linearity was evaluated for some variables. Indeed, we developed two severity risk scores (for
mortality up to 1 and 2 years) by assigning a weight to each risk factor category based on the β
parameter from the multivariable Cox proportional-hazards regression. Then we added the
weights of each of the risk factors presented by a patient with a higher score corresponding to
a higher likelihood of mortality. Considering the optimal classifier points, three severity cate-
gories were created in each score.[16]
The predictive accuracy of each model was determined by the C-index. The predictive
capacity of the risk groups derived from the models was also evaluated and validated in both
samples by calculating the area under the receiver operating characteristic curve (AUC) and
the calibration of the models was tested by Hosmer-Lemeshow test. All effects were considered
significant at p< 0.05. All statistical analyses were performed using SAS 9.4 software (SAS
Institute Inc., Cary, NC, USA).
Results
We initially contacted 2832 patients. Of these patients, 1979 fulfilled the selection criteria, with
1942 patients having full information at 1 year and 1817 at 2 years of follow-up as displayed in
“Fig 1”.
Table 1 shows the descriptive of the derivation, validation and whole samples. Table 2
shows the different chemotherapy strategies employed in our patients. Univariable analysis in
the derivation sample of the relationship of different sociodemographic and clinically relevant
variables after 30 days from surgery with mortality at 1 (6.58% mortality rate) and 2 years
(6.59% mortality rate) is displayed in Table 3.
Table 4 shows, based on the multivariable analysis, predictors of 1-year mortality were the
ASA IV, a score 4 in the Charlson comorbidity index (CCI), age older than 75 years, TNM
stage IV, lymph nodes ratio (>-0.53) and the residual tumor classification (R2 vs. R0-R1 cate-
gories). All the significant variables in the derivation sample were also significant in the valida-
tion sample. The C-index showed a good discrimination for both samples (0.865 (0.792–0.938)
and 0.808 (0.734–0.882), in the derivation and validation samples, respectively). When includ-
ing the treating hospital in the model, the C-index rose to 0.881 (0.807–0.955) in the derivation
sample and 0.852 (0.776–0.928) in the validation sample. Since the use of adjuvant chemother-
apy after 30 days of surgery has a role in survival, this variable was introduced as an interaction
term with TNM stage. C-indexes were 0.885 (0.797–0.973) in the derivation and 0.848 (0.762–
0.934) in the validation sample and, when including the treating hospital, the C-indexes were
0.914 (0.828–1.000) and 0.898 (0.810–0.986) in the derivation and validation samples,
respectively.
Predictors of mortality during the first 2 years after surgery were the same as those that pre-
dicted mortality during the first year (Table 5). The C-index showed a good discrimination for
both samples (0.808 (0.751–0.865) and 0.796 (0.739–0.853) in the derivation and validation
samples, respectively). When including the treating hospital in the model, the C-index rose to
0.832 (0.775–0.888) in the derivation sample and 0.819 (0.762–0.876) in the validation sample.
When chemotherapy was included in the model C-indexes were 0.808 (0.749–0.867) in the
derivation and 0.817 (0.760–0.874) in the validation sample and, when including the treating
hospital, the C-indexes were 0.836 (0.777–0.895) and to 0.834 (0.775–0.893), respectively.
The predictive accuracy of each continuous and categorical risk scores for 1-year mortality
and 2-year mortality were measured by the AUCs which are displayed in Table 6. The AUC of
the continuous risk score for 1-year mortality was 0.876 (0.828–0.924) in the derivation sample
Risk scores of colon cancer mortality
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Fig 1. Flow-chart of the recruitment and follow-up process.
https://doi.org/10.1371/journal.pone.0199894.g001
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and 0.780 (0.715–0.845) in the validation sample, without considering adjuvant chemotherapy.
However, including adjuvant chemotherapy, the AUCs of the continuous risk score were
0.882 (0.826–0.939) and 0.791 (0.718–0.864) in the derivation and validation samples,
Table 1. Descriptive sociodemographic and clinical statistics of all samples of the study.
N (%) Sample p-value
Derivation N (%) Validation N (%)
Total 1945 972 (49.97) 973 (50.03)
Gender (Male) 1205 (61.95) 611 (62.86) 594 (61.05) 0.4106
Age 0.3674
•75 1339 (68.95) 678 (69.90) 661 (68.00)
• >75 603 (31.05) 292 (30.10) 311 (32.00)
Haemoglobin at baseline 12.33 (2.15) 12.38 (2.12) 12.28 (2.17) 0.3834
Charlson index 0.8181
• <4 1511 (77.69) 753 (77.47) 758 (77.90)
•4 434 (22.31) 219 (22.53) 215 (22.10)
ASA 0.4318
• I,II,III 1817 (95.93) 908 (95.58) 909 (96.29)
• IV 77 (4.07) 42 (4.42) 35 (3.71)
Type of surgery 0.6986
• Laparoscopy 1138 (59.02) 566 (58.59) 572 (59.46)
• Open Surgery 790 (40.98) 400 (41.41) 390 (40.54)
Organ invasión 0.2322
• 0 1741 (89.51) 860 (88.48) 881 (90.54)
• 1 167 (8.59) 94 (9.67) 73 (7.50)
• >1 37 (1.90) 18 (1.85) 19 (1.95)
Result of the surgery 0.4683
• R0 1741 (93.10) 862 (92.39) 879 (93.81)
• R1 72 (3.85) 39 (4.18) 33 (3.52)
• R2 57 (3.05) 32 (3.43) 25 (2.67)
Log Lymph nodes ratio 0.5683
•-1.36 1528 (81.62) 754 (80.99) 774 (82.25)
• -1.36<-0.53 184 (9.83) 91 (9.77) 93 (9.88)
• -0.53< 160 (8.55) 86 (9.24) 74 (7.86)
Length of stay† 9 [7–14] 9 [7–14] 9 [7–13] 0.3787
Adjuvant Chemotherapy and pTNM 0.3078
• No chemo and pTNM 0, I, II 842 (43.88) 399 (41.74) 443 (46.00)
• Yes chemo and pTNM 0, I, II 238 (12.40) 127 (13.28) 111 (11.53)
• No chemo and pTNM III 157 (8.18) 87 (9.10) 70 (7.27)
• Yes chemo and pTNM III 501 (26.11) 247 (25.84) 254 (26.38)
• No chemo and pTNM IV 35 (1.82) 19 (1.99) 16 (1.66)
• Yes chemo and pTNM IV 146 (7.61) 77 (8.05) 69 (7.17)
Outcomes
Mortality up to 1 year 121 (6.22) 62 (6.38) 59 (6.06) 0.7738
Mortality up to 2 years 236 (12.13) 118 (12.14) 118 (12.13) 0.9933
N: Frequency, %: Percentage
Results shown as mean (standard deviation).
†Results shown as median [25th percentil– 75th percentil].
R-stage of the operation. Residual tumor (R) classification: R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor
https://doi.org/10.1371/journal.pone.0199894.t001
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respectively. A risk score was also developed for 2-year mortality. The AUCs were 0.806
(0.760–0.851) in the derivation sample and 0.807 (0.758–0.856) in the validation sample, with-
out considering adjuvant chemotherapy. Including adjuvant chemotherapy, the AUCs of the
continuous risk score were 0.804 (0.758–0.850) and 0.805 (0.756–0.855) in the derivation and
validation samples, respectively. From the previous risk score, two categorical risk scores, with
three categories each, were developed for both mortality periods (Table 6). The three risk cate-
gories of each risk score, for 1- or 2-year mortality, differentiated among the categories. The
categorical risk scores developed showed AUCs of 0.854 (0.796–0.912) in the derivation sam-
ple and 0.766 (0.692–0.841) in the validation sample for 1-year mortality. For 2-year mortality,
the AUCs for the derivation and validation sample were, respectively, 0.776 (0.725–0.826) and
0.779 (0.729–0.829), both including adjuvant chemotherapy. However, without considering
adjuvant chemotherapy, the categorical risk scores developed showed AUCs of 0.838 (0.793–
0.883) and 0.768 (0.708–0.827) in the derivation and validation samples, respectively, for
1-year mortality. For 2-year mortality, the AUCs for the derivation and validation samples
were, respectively, 0.770 (0.722–0.818) and 0.778 (0.727–0.829). All the results were estimated
without considering the effect of the treating hospital. As additional information, internal vali-
dation of all the models were performed where it can be seen that those variables selected for
our 4 models are the ones more often obtained by bootstrap (Table 7).
To better display the final results, trees charts derived from previous Tables 4 and 5 and the
weights of the categories of the statistically significant variables and based on risk categories
of Table 6 were developed. “Figs 2 and 3” presents the display for predicting mortality at one
year with and without chemotherapy. “Figs 4 and 5” present similar trees but for two years
mortality.
Discussion
This prospective cohort study included a large sample of 1942 patients with colon cancer who
underwent curative or palliative surgery. We identified factors before the intervention and up
to 30 days and 1 year afterwards that related to mortality at 1 and 2 years in these patients. The
categories of those factors were weighted to create continuous scores that, ultimately, were cat-
egorized into three categories of risk clinical prediction rules from minor to severe, based on
the risk of dying at those points in time. Different prediction rules, though based in the same
variables, were created for 1- and 2-year mortality, and, in each case, based on information
Table 2. Descriptive statistics of the adjuvant chemotherapy and molecular targeted agents employed in each sample.
N (%) Sample p-valor
Derivation N (%) Validation N (%)
Total 1945 972 (49.97) 973 (50.03)
Adjuvant chemotherapy 892 (46.19) 457 (47.46) 435 (44.94) 0.2672
• Folfox (Fluorouracil, Oxaliplatin) 239 (12.38) 128 (13.29) 111 (11.47) 0.2234
• Folfiri (Fluorouracil, Irinotecan, folinic acid) 50 (2.59) 25 (2.60) 25 (2.58) 0.9852
• Capeox/Xelox (Capecitabine, Oxaliplatin) 429 (22.22) 226 (23.47) 203 (20.97) 0.1869
• Fluorouracil 8 (0.41) 2 (0.21) 6 (0.62) 0.2881
• Fluoruracil-Leucovorı́n 30 (1.55) 17 (1.77) 13 (1.34) 0.4531
• Monotherapy 169 (8.75) 69 (7.17) 100 (10.33) 0.0139
Molecular targeted agents 107 (5.61) 59 (6.20) 48 (5.02) 0.2593
N: Frequency, %: Percentage
https://doi.org/10.1371/journal.pone.0199894.t002
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Table 3. Univariable analysis in the derivation sample for mortality up to 1 and 2 years.
Univariable analysis
Mortality up to 1 year HR (95% CI) p-value Mortality up to 2 years HR (95% CI) p-value
Total‡ 64 (6.58) 124 (12.76)
Age
•75 Ref. Ref.
• >75 2.435 (1.473–4.026) 0.0005 2.185 (1.520–3.142) <0.0001
Haemoglobin at baseline 0.985 (0.953–1.018) 0.3627 0.990 (0.973–1.008) 0.2646
Charlson index
• <4 Ref. Ref.
•4 2.199 (1.307–3.701) 0.0030 1.729 (1.174–2.546) 0.0056
ASA
• I,II,III Ref. Ref.
• IV 4.889 (2.404–9.942) <0.0001 4.187 (2.393–7.326) <0.0001
Type of surgery
• Laparoscopy Ref. Ref.
• Open surgery 1.789 (1.064–3.008) 0.0284 1.590 (1.100–2.297) 0.0135
Organ invasion
• 0 Ref. Ref.
• 1 2.747 (1.433–5.268) 0.0023 2.939 (1.879–4.598) <0.0001
• >1 13.196 (6.413–27.154) <0.0001 8.411 (4.366–16.203) <0.0001
Tumor sidedness
• Right 1.529 (0.921–2.536) 0.1005 1.583 (1.101–2.275) 0.0131
• Left Ref. Ref.
Histology
• Adenocarcinoma Ref. Ref.
• Others 2.357 (1.344–4.133) 0.0028 1.926 (1.259–2.945) 0.0025
Result of the surgery
• R0 Ref. Ref.
• R1 3.618 (1.415–9.250) 0.0073 2.924 (1.467–5.827) 0.0023
• R2 15.624 (8.896–27.442) <0.0001 11.562 (7.399–18.070) <0.0001
Log Lymph nodes ratio
•-1.36 Ref. Ref.
• -1.36<-0.53 4.106 (1.933–8.719) 0.0002 3.196 (1.918–5.325) <0.0001
• -0.53< 10.251 (5.647–18.607) <0.0001 5.997 (3.865–9.307) <0.0001
Length of stay† 1.015 (1.007–1.024) 0.0005 1.013 (1.006–1.020) 0.0002
Adjuvant Chemotherapy and pTNM
• No chemo and pTNM 0, I, II Ref. Ref.
• Yes chemo and pTNM 0, I, II 1.132 (0.235–5.447) 0.8774 0.789 (0.270–2.307) 0.6646
• No chemo and pTNM III 10.688 (4.357–26.217) <0.0001 7.071 (3.947–12.670) <0.0001
• Yes chemo and pTNM III 2.016 (0.750–5.417) 0.1644 1.934 (1.068–3.501) 0.0294
• No chemo and pTNM IV 24.276 (7.702–76.516) <0.0001 14.057 (5.940–33.267) <0.0001
• Yes chemo and pTNM IV 10.756 (4.251–27.212) <0.0001 9.491 (5.328–16.906) <0.0001
Excluded patient who died throughout the admission or during the first 30 days after admission
Results shown as mean (standard deviation).
†Results shown as median [25th percentil– 75th percentil].
‡Frequency (percentage) of patients who die up to 1 year or up to 2 years.
† HR: Hazard Ratio. CI: Confidence Interval
†HR estimated for a unit increase.
R-stage of the operation. Residual tumor (R) classification: R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor.
https://doi.org/10.1371/journal.pone.0199894.t003
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available before surgery, during the index admission, and up to 30 days after surgery when, we
took into account whether adjuvant chemotherapy was administered.[8–10, 18, 19]
We identified as predictors of medium-term mortality parameters such as ASA and comor-
bidities (based on the CCI). These are parameters related to the general condition of the
patient before surgery, and are quite easily available for review. Similarly, older age can be
related to higher frailty and need to be institutionalized or were more likely to undergo colon
cancer resection during an unscheduled admission, which has been shown to be related to a
higher rate of death in this patients. [20] We also identified TNM stage and lymph nodes ratio,
which are related to the severity of the current disease, as a predictor of medium-term mortal-
ity. Finally, the residual tumor (R) classification, which is also related to the severity of the dis-
ease as well as reflects the result of surgery, had an influence on 1-year mortality. On the other
hand, around 30 days after surgery is usually when, if it is indicated, the patient will begin
Table 4. Predictors of mortality at 1 year in patients with colon cancer. Multivariate Cox regression analysis.
Derivation sample Weight Validation sample
β (s.e.) HR (CI 95%) p-value β (s.e.) HR (CI 95%) p-value
ASA (IV vs. I,II,III) 1.20 (0.40) 3.334 (1.509–7.367) 0.0029 3 1.55 (0.38) 4.693 (2.207–9.977) <0.0001
Charlson index (4 vs.4) 1.20 (0.29) 3.330 (1.884–5.886) <0.0001 3 0.66 (0.28) 1.942 (1.123–3.358) 0.0175
Age (>75 vs.75) 1.63 (0.29) 5.112 (2.893–9.035) <0.0001 4 0.60 (0.28) 1.825 (1.055–3.157) 0.0315
pTNM
• III (vs. 0,I,II) -0.11 (0.41) 0.900 (0.403–2.011) 0.7976 0 0.67 (0.37) 1.955 (0.950–4.023) 0.0688
• IV (vs. 0,I,II) 1.52 (0.45) 4.566 (1.895–10.999) 0.0007 4 1.11 (0.44) 3.024 (1.288–7.100) 0.0110
Results of the surgery (R2 vs. R0-R1) 1.11 (0.40) 3.044 (1.381–6.709) 0.0058 3 2.06 (0.41) 7.817 (3.485–17.532) <0.0001
Log Lymph nodes ratio
• -1.36<-0.53 (vs.-1.36) 0.94 (0.46) 2.554 (1.035–6.298) 0.0418 0 -0.04 (0.46) 0.961 (0.393–2.351) 0.9312
• -0.53< (vs.-1.36) 2.21 (0.38) 9.156 (4.325–19.381) <0.0001 5 1.01 (0.35) 2.758 (1.399–5.439) 0.0034
C-index (95% CI) 0.865 (0.792–0.938) 0.808 (0.734–0.882)†
Adjuvant chemotherapy included
ASA (IV vs. I,II,III) 1.42 (0.46) 4.130 (1.674–10.190) 0.0021 3 1.22 (0.46) 3.383 (1.378–8.303) 0.0078
Charlson index (4 vs.4) 1.13 (0.36) 3.101 (1.524–6.310) 0.0018 2 0.57 (0.31) 1.767 (0.959–3.258) 0.0681
Age (>75 vs.75) 1.44 (0.36) 4.216 (2.074–8.570) <0.0001 3 0.64 (0.33) 1.906 (0.991–3.666) 0.0532
Adjuvant Chemotherapy and pTNM
• No and III (vs. Yes/No and 0,I,II) 0.26 (0.56) 1.303 (0.434–3.914) 0.6371 0 1.55 (0.44) 4.702 (1.990–11.106) 0.0004
• Yes and III (vs. Yes/No and 0,I,II) -0.01 (0.58) 0.989 (0.319–3.065) 0.9850 0 -0.28 (0.63) 0.759 (0.223–2.586) 0.6589
• No and IV (vs. Yes/No and 0,I,II) 1.92 (0.68) 6.829 (1.786–26.109) 0.0050 4 1.60 (0.66) 4.967 (1.359–18.155) 0.0154
• Yes and IV (vs. Yes/No and 0,I,II) 1.34 (0.63) 3.812 (1.103–13.168) 0.0344 3 1.09 (0.53) 2.965 (1.048–8.384) 0.0405
Results of the surgery (R2 vs. R0-R1) 1.37 (0.50) 3.950 (1.473–10.593) 0.0063 3 2.20 (0.44) 9.016 (3.838–21.181) <0.0001
Log Lymph nodes ratio
• -1.36<-0.53 (vs.-1.36) 1.23 (0.53) 3.421 (1.218–9.606) 0.0196 0 0.32 (0.50) 1.376 (0.519–3.649) 0.5210
• -0.53< (vs.-1.36) 2.35 (0.46) 10.487 (4.249–25.880) <0.0001 5 1.02 (0.40) 2.771 (1.259–6.096) 0.0113
C-index (95% CI) 0.885 (0.797–0.973)‡ 0.848 (0.762–0.934)§
C-index: Concordance index. β: estimation. s.e.: standard error. HR: Hazard Ratio. CI: Confidence Interval. %: Percentage. vs.: versus.
Model without adjuvant chemotherapy included patients who died throughout the index hospital admission until one year after admission.
Model including adjuvant chemotherapy excluded patients who died throughout the index hospital admission or during the first 30 days after admission.
Including the hospital (p = 0.9943), the c-index rise to 0.881 (0.807–0.955).
†Including the hospital (p = 0.8405), the c-index rise to 0.852 (0.776–0.928). In both case, statistically significant differences among some hospitals were found.
‡Including the hospital (p = 0.9141), the c-index rise to 0.914 (0.828–1.000).
§Including the hospital (p = 0.6881), the c-index rise to 0.898(0.810–0.986). In both case, statistically significant differences among some hospitals were found.
https://doi.org/10.1371/journal.pone.0199894.t004
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chemotherapy for colon cancer. Adjuvant chemotherapy, as a specific treatment of the disease,
has a clear relationship with mortality that changes depending on TNM stage. Therefore, a sec-
ond set of prediction rules added chemotherapy treatment in conjunction with TNM stage to
the previous parameters.
All of the predictors for 1-year mortality also appeared as predictors of 2-year mortality.
These included those related to the general condition of the patient, such as age, ASA and CCI,
but the main influence was from factors related to colon cancer and the patient’s evolution,
including TNM stage. As with 1-year mortality, disease treatment, specifically adjuvant che-
motherapy in relation to TNM stage, had a clear relationship with 2-year mortality.
Previous studies have found that disease severity, in this case, colon cancer stage as mea-
sured by TNM or lymph node status, or number of positive lymph nodes, or depth of primary
tumor penetration are predictors of mortality.[21] Additionally, comorbidities, as measured
by the Charlson comorbidity index in our case, jointly with age, have also been shown to affect
Table 5. Predictors of mortality at 2 year in patients with colon cancer. Multivariate Cox regression analysis.
Derivation sample Weight Validation sample
β (s.e.) HR (CI 95%) p-value β (s.e.) HR (CI 95%) p-value
ASA (IV vs. I,II,III) 0.80 (0.34) 2.223 (1.152–4.291) 0.0172 2 1.49 (0.32) 4.443 (2.389–8.263) <0.0001
Charlson index (4 vs.4) 0.73 (0.22) 2.077 (1.342–3.214) 0.0010 2 0.82 (0.22) 2.280 (1.492–3.484) 0.0001
Age (>75 vs.75) 1.12 (0.21) 3.071 (2.017–4.675) <0.0001 3 0.92 (0.21) 2.518 (1.653–3.835) <0.0001
pTNM
• III (vs. 0,I,II) 0.77 (0.29) 2.153 (1.229–3.774) 0.0074 2 0.77 (0.28) 2.151 (1.237–3.740) 0.0067
• IV (vs. 0,I,II) 2.07 (0.33) 7.932 (4.192–15.012) <0.0001 5 1.51 (0.33) 4.546 (2.358–8.764) <0.0001
Results of the surgery (R2 vs. R0-R1) 1.25 (0.31) 3.496 (1.901–6.428) <0.0001 3 1.62 (0.38) 5.069 (2.430–10.574) <0.0001
Log Lymph nodes ratio
• -1.36<-0.53 (vs.-1.36) 0.50 (0.30) 1.655 (0.915–2.994) 0.0959 0 0.29 (0.32) 1.332 (0.707–2.511) 0.3747
• -0.53< (vs.-1.36) 1.22 (0.27) 3.389 (1.979–5.803) <0.0001 3 1.09 (0.28) 2.982 (1.739–5.113) <0.0001
C-index (95% CI) 0.808 (0.751–0.865) 0.796 (0.739–0.853)†
Adjuvant chemotherapy included
ASA (IV vs. I,II,III) 0.84 (0.34) 2.306 (1.175–4.525) 0.0152 2 1.31 (0.33) 3.711 (1.945–7.083) <0.0001
Charlson index (4 vs.4) 0.73 (0.23) 2.074 (1.318–3.264) 0.0016 2 0.78 (0.22) 2.173 (1.421–3.325) 0.0003
Age (>75 vs.75) 1.14 (0.24) 3.130 (1.971–4.970) <0.0001 3 0.74 (0.23) 2.093 (1.341–3.266) 0.0011
Adjuvant Chemotherapy and pTNM
• No and III (vs. Yes/No and 0,I,II) 0.79 (0.36) 2.214 (1.099–4.459) 0.0261 2 1.36 (0.32) 3.904 (2.103–7.246) <0.0001
• Yes and III (vs. Yes/No and 0,I,II) 0.79 (0.33) 2.196 (1.162–4.153) 0.0155 2 0.15 (0.35) 1.158 (0.583–2.299) 0.6756
• No and IV (vs. Yes/No and 0,I,II) 2.02 (0.49) 7.516 (2.875–19.651) <0.0001 5 1.53 (0.50) 4.608 (1.740–12.199) 0.0021
• Yes and IV (vs. Yes/No and 0,I,II) 1.95 (0.37) 7.037 (3.389–14.612) <0.0001 5 1.42 (0.38) 4.151 (1.983–8.689) 0.0002
Results of the surgery (R2 vs. R0-R1) 1.35 (0.34) 3.855 (1.988–7.476) <0.0001 4 1.54 (0.38) 4.674 (2.226–9.815) <0.0001
Log Lymph nodes ratio
• -1.36<-0.53 (vs.-1.36) 0.58 (0.31) 1.787 (0.974–3.279) 0.0608 0 0.36 (0.33) 1.434 (0.758–2.714) 0.2681
• -0.53< (vs.-1.36) 1.17 (0.29) 3.225 (1.820–5.715) <0.0001 3 1.13 (0.29) 3.090 (1.765–5.409) <0.0001
C-index (95% CI) 0.808 (0.749–0.867)‡ 0.817 (0.760–0.874)§
C-index: Concordance index. β: estimation. s.e.: standard error. HR: Hazard Ratio. CI: Confidence Interval. %: Percentage. vs.: versus.
Excluded patients who died throughout the index hospital admission or during the first 30 days after admission. Including patients who died during 1 year.
Including the hospital (p = 0.4066), the c-index rise to 0.832 (0.775–0.888).
†Including the hospital (p = 0.2459), the c-index rise to 0.819 (0.762–0.876). In both case, statistically significant differences among some hospitals were found.
‡Including the hospital (p = 0.1713), the c-index rise to 0.836 (0.777–0.895).
§ Including the hospital (p = 0.3760), the c-index rise to 0.834 (0.775–0.893). In both case, statistically significant differences among some hospitals were found.
https://doi.org/10.1371/journal.pone.0199894.t005
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mortality.[8, 20, 22, 23] Some studies have also implicated ASA level in mortality in colon can-
cer patients.[18, 24] Parameters from the evolution of disease in colon cancer patients, such as
complications and reoperations, also were found to be predictive by some authors. Addition-
ally, adjuvant chemotherapy was also a predictive factor in some studies, as in ours.[25] How-
ever, we first wanted to know which factors were predictors of mortality without considering
chemotherapy. We introduced an interaction term to determine the different effects that che-
motherapy had, depending on the TNM grade of the tumor. Additional variables, such as gen-
der (a parameter that arose in some studies) and race, were not predictive in our analysis.[18,
26]
Table 6. Categorical risk scores prediction of mortality at 1 or 2 years after surgery.
Derivation sample Validation sample
Total Mortality p-value Total Mortality p-value
a. No Adjuvant Chemotherapy included
Mortality up to 1 year score
Risk score AUC (95% CI) 0.876 (0.828–0.924) 0.780 (0.715–0.845)
Risk groups <0.0001 <0.0001
• 0 402 (44.92) 3 (0.75) 419 (46.50) 8 (1.91)
• 1–5 305 (34.08) 10 (3.28) 320 (35.52) 17 (5.31)
•6 188 (21.01) 47 (25.00) 162 (17.98) 37 (22.84)
AUC (95% CI) 0.838 (0.793–0.883) 0.768 (0.708–0.827)
p Hosmer-Lemeshow test 1.0000 0.9999
Mortality up to 2 years score
Risk score AUC (95% CI) 0.806 (0.760–0.851) 0.807 (0.758–0.856)
Risk groups <0.0001 <0.0001
• 0–2 464 (52.49) 16 (3.45) 481 (54.11) 18 (3.74)
• 3–5 305 (34.50) 37 (12.13) 313 (35.21) 32 (10.22)
•6 115 (13.01) 47 (40.87) 95 (10.69) 48 (50.53)
AUC (95% CI) 0.770 (0.722–0.818) 0.778 (0.727–0.829)
p Hosmer-Lemeshow test 1.0000 1.0000
b. Adjuvant Chemotherapy included
Mortality up to 1 year score
Risk score AUC (95% CI) 0.882 (0.826–0.939) 0.791 (0.718–0.864)
Risk groups <0.0001 <0.0001
• 0–2 483 (55.07) 3 (0.62) 504 (56.88) 10 (1.98)
• 3–6 325 (37.06) 14 (4.31) 321 (36.23) 16 (4.98)
•7 69 (7.87) 25 (36.23) 61 (6.88) 22 (36.07)
AUC (95% CI) 0.854 (0.796–0.912) 0.766 (0.692–0.841)
p Hosmer-Lemeshow test 1.0000 1.0000
Mortality up to 2 years score
Risk score AUC (95% CI) 0.804 (0.758–0.850) 0.805 (0.756–0.855)
Risk groups <0.0001 <0.0001
• 0–3 551 (62.83) 20 (3.63) 594 (67.04) 23 (3.87)
• 4–7 263 (29.99) 39 (14.83) 237 (26.75) 40 (16.88)
•8 63 (7.18) 34 (53.97) 55 (6.21) 33 (60.00)
AUC (95% CI) 0.776 (0.725–0.826) 0.779 (0.729–0.829)
p Hosmer-Lemeshow test 0.9999 0.9990
AUC: Area Under the receiver operative Curve. %: Percentage, CI: Confidence Interval.
https://doi.org/10.1371/journal.pone.0199894.t006
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Most studies working on the identification of predictors of mortality in patients with colon
cancer have focused on perioperative, in-hospital, or short-term mortality (up to 30 days post-
operation). In this study, we explicitly removed this short-term mortality from our outcomes.
We wanted to avoid the influence of surgeon ability, complications related to the surgery, and
hospital health care quality in our prediction. However, as we have shown in our results, the
variable of the treating hospital did have an influence on the 1- and 2-year mortality, and we
have adjusted for it in our models. This means that the specific health care location has a role
in explaining the causes of mortality, which indicates a possible problem of variability and
equity among our centers.[26, 27]
From a practical point of view, our summary trees are developed to have a quick and simul-
taneous view of the prognosis of a patient at one and two years after surgery just at the time of
the index admission-without chemotherapy- and, additionally, at 30 days afterwards, when
chemotherapy is added. In general terms, mortality is low and remains similar at 1 an 2 years
Table 7. Percentage of times each variable was selected by stepwise selection in internal validation using bootstrap.
Predictors of mortality at 1 year in patients with colon
cancer
Predictors of mortality at 2 years in patients with colon
cancer
At index admission % At 30 days (chemotherapy)% At index admission % At 30 days (chemotherapy)%
Possible predictors
Age 100 96 100 100
Haemoglobin at baseline 72 18 59 44
Charlson index 95 91 86 91
ASA 71 77 52 68
Type of surgery 55 13 5 7
Organ invasion 9 0 6 3
Tumor sidedness 14 11 25 23
Histology 34 2 18 9
Result of the surgery 73 76 92 93
Log lymph node ratio 100 100 96 95
pTNM 98 — 100 —
Adjuvant Chemotherapy and pTNM — 91 — 100
%: Percentage.
https://doi.org/10.1371/journal.pone.0199894.t007
Fig 2. Detail of risk factors associated to one-year mortality risk categories. Risk factors include: ASA = IV, Charlson index4, age>75 years, results of the
surgery = R2 and Log lymph nodes ratio>-0.53.
https://doi.org/10.1371/journal.pone.0199894.g002
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for TNM 0/I/II with no risk factors or just the Charlson comorbidity index4. On the oppo-
site side, is high for TNM IV or III with additional risk factors based on our rules. Those
graphics can help clinicians as well as patients.
This study has several strengths. It was based on a large prospective cohort obtained from
22 hospitals, thus providing variability. The number of variables on the possible predictors of
death was quite large. We have also included models with and without chemotherapy. The
development of the predictive models followed the structure of current guidelines, such as
those included in the TRIPOD statement [28], including an internal and external validation of
all models. We identified predictive factors common to various other studies. However, the
strength of our study lies in the fact that we have put them together, with just a few variables
Fig 3. Detail of risk factors associated to one-year mortality risk categories, chemotherapy included. Risk factors include: ASA = IV, Charlson index4, age>75
years, results of the surgery = R2 and Log lymph nodes ratio>-0.53.Minor risk factor: Charlson index4. †Moderate risk factors: ASA = IV, age>75 years and results
of the surgery = R2. ‡Severe risk factor: Log lymph nodes ratio>-0.53.
https://doi.org/10.1371/journal.pone.0199894.g003
Fig 4. Detail of risk factors associated to two-years mortality risk categories. Risk factors include: ASA = IV, Charlson index4, age>75 years, results of the
surgery = R2 and Log lymph nodes ratio>-0.53.Minor risk factor: Charlson index4 and ASA = IV. †Moderate risk factors: age>75 years, results of the surgery = R2
and Log lymph nodes ratio>-0.53.
https://doi.org/10.1371/journal.pone.0199894.g004
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that are usually recorded and easily accessed, into single scores that may help clinicians easily
and quickly classify the prognosis of these patients. As our scores have excellent predictive abil-
ity, clinicians will be better able to guide patients in follow-up. These scores may also serve as a
reference to patients and families.
However, this study also has limitations. As in any prospective multicenter study with a
2-year follow-up, loss to follow-up was our main source of bias. Though reviewers in each cen-
ter were trained to collect all of the planned information from all of the patients recruited at
baseline, loss of patients and information was inevitable, though contained. We did study the
influence of various HRQoL parameters in our outcomes, but, surprisingly, none of the ques-
tionnaires studied, even those detailing markers of frailty or health status, showed any predic-
tive influence on mortality. Additionally, none of the tumor biomarkers studied, such as
carcinoembryonic antigen levels, showed any relationship with mortality. Nevertheless, as new
genetic and biological markers are discovered, they should be considered for addition to our
models to increase predictive ability. Even further, improvements in the treatment of these
patients, as the addition of new and more effective drugs, may change the predictive ability of
our models though more than 50% of our patients did not receive chemotherapy and just
those more severe received the new molecular targeted agents. We also did not do in-depth
analysis on the influence of the quality, appropriateness, or existence of errors in the health
care to the patients, or adherence to various treatments for the disease and comorbidities,
when all of these factors could have a clear influence on mortality.
Finally, there are various statistical techniques currently used to develop clinical prediction
rules. The ones we used in our study, namely, survival and logistic regression models, are clas-
sical but robust and clear for reading comprehension. Other techniques that have been
employed in other studies, such as neural networks or a Bayesian belief network, may be alter-
natives, though some of them have a “black box” effect, wherein the design of the model is
obscure to the reader. They are also usually no superior to the classical techniques.[10, 18, 29]
Fig 5. Detail of risk factors associated to two-year mortality risk categories, chemotherapy included. Risk factors include: ASA = IV, Charlson index4, age>75
years, results of the surgery = R2 and Log lymph nodes ratio>-0.53.Minor risk factor: Charlson index4 and ASA = IV. †Moderate risk factors: age>75 years and Log
lymph nodes ratio>-0.53. ‡Severe risk factor: results of the surgery = R2. NA: Not applicable.
https://doi.org/10.1371/journal.pone.0199894.g005
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As with any clinical prediction rule, proper external validation of our proposed models is the
necessary next step, and, from a practical clinical point of view, studies are needed where the
use of these rules improve patient health care.[30]
In conclusion, these clinical prediction rules provide clinicians and patients with decision
tools that, with a minimal amount of easily obtainable information, have shown good predic-
tive abilities and can be used in the clinical decision process. They provide information before
starting the chemotherapy treatment process and are also valuable tools once the chemother-
apy treatment has started in those patients where it has been prescribed since we present mod-
els for both situations. Lastly, future studies should examine the validity of our models in other
settings, as well as apply them in real-life situations to determine their usefulness in the patient
care and management process.
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Supervision: José M. Quintana, Santiago Lázaro, Maximino Redondo, Eduardo Briones,
Antonio Escobar, Cristina Sarasqueta.
Validation: Ane Antón-Ladislao, Nerea González, Susana Garcı́a-Gutierrez, Inmaculada
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